Financial Performance - The total operating revenue for the reporting period is approximately ¥327,999,607, a decrease of 3.24% compared to the previous year[3] - The net profit attributable to shareholders is approximately ¥31,702,213, reflecting a decline of 9.09% year-on-year[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses is approximately ¥30,017,563, down 12.74% from the previous year[3] - The basic earnings per share is estimated at ¥0.18, a decrease of 10.00% compared to the same period last year[3] Assets and Equity - Total assets at the end of the reporting period are approximately ¥483,523,075, an increase of 0.20% year-on-year[4] - Shareholders' equity attributable to the company is approximately ¥389,682,647, reflecting a growth of 0.08% compared to the beginning of the period[4] Market Challenges - The company faced challenges due to international political changes and ongoing geopolitical conflicts, leading to reduced sales volume and orders from some clients[5] Strategic Actions - The company increased its participation in domestic and international industry exhibitions and boosted cross-border e-commerce investments, resulting in higher sales expenses[5] - The company’s gross profit margin improved due to the depreciation of the RMB against the USD, although exchange gains decreased compared to the previous year[5] Financial Caution - The financial data presented is preliminary and has not been audited, cautioning investors to be aware of investment risks[6]
鹿得医疗(832278) - 2023 Q4 - 年度业绩